Compare BioNano Genomics Inc (BNGO) vs Chubb Ltd (CB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Chubb Ltd — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.31M), while Chubb Ltd trades at $347 (market cap $134.37B). The key difference: Chubb Ltd is far larger — about 10095.4× BioNano Genomics Inc's market cap, and Chubb Ltd pays a 1.17% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | CB | |
|---|---|---|
Market Cap | $13.31M | $134.37B |
Sector | Health | Financials |
52-Week High | $4.92 | $363.50 |
52-Week Low | $1.06 | $268.20 |
Enterprise Value | $15.92M | $155.22B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.16, up 5.45% today, with a bullish technical signal from moving averages. The company shows improving financial trends with revenue stabilizing around $29M annually and narrowing losses from -$232M in 2023 to -$26M in 2025. Recent earnings beats and positive news flow around optical genome mapping adoption support momentum.
While BNGO demonstrates operational improvement and analyst support (57% buy ratings), the stock faces significant risks including persistent negative profitability, cash burn requiring ongoing financing, and competitive pressures in genomic technology. The current valuation appears attractive on P/S and P/B metrics but reflects the company's pre-profitability stage.
Chubb (CB) trades at $350.31, down 1.05% on the day, with a neutral technical signal and bullish moving averages. The stock shows strong fundamentals, with Q2 2026 EPS of $7.26 beating estimates, revenue growth to $59.78B in 2025, and a net income margin of 17.96%. Recent news highlights leadership appointments and positive earnings coverage.
The outlook is positive, supported by consistent earnings beats, a 52.38% analyst buy rating, and a consensus price target of $366.83. Risks include macroeconomic sensitivity and competitive pressures in insurance. The stock presents a value opportunity with a P/E of 12.41 and robust cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Chubb Ltd
ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination makes the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
Read more on CB →
